SO

SOLA Biosciences

3 known investors

sola-bio.com ↗

SOLA Biosciences develops gene therapies for conformational diseases, using its JUMP70 platform to activate the body's protein-folding machinery to refold or remove misfolded proteins. Its lead candidate SOL-257 is a single-dose gene therapy targeting toxic TDP-43 protein aggregates in ALS.

Investors · 3

EI

Eisai Innovation, Inc.San Francisco

MC

MC Healthcare VenturesCambridge

UT

UTECTokyo · $3.1M – $78M